ACADIA Pharmaceuticals Inc. (ACAD)
NASDAQ: ACAD · IEX Real-Time Price · USD
31.31
-0.08 (-0.24%)
At close: Dec 29, 2023, 4:00 PM
32.00
+0.69 (2.20%)
After-hours: Dec 29, 2023, 7:18 PM EST
ACADIA Pharmaceuticals Employees
ACADIA Pharmaceuticals had 514 employees on December 31, 2021. The number of employees decreased by 87 or -14.48% compared to the previous year.
Employees
514
Change (1Y)
-87
Growth (1Y)
-14.48%
Revenue / Employee
$1,229,350
Profits / Employee
-$289,510
Market Cap
5.14B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2021 | 514 | -87 | -14.48% |
Dec 31, 2020 | 601 | 98 | 19.48% |
Dec 31, 2019 | 503 | 73 | 16.98% |
Dec 31, 2018 | 430 | 5 | 1.18% |
Dec 31, 2017 | 425 | 55 | 14.86% |
Dec 31, 2016 | 370 | 210 | 131.25% |
Dec 31, 2015 | 160 | 63 | 64.95% |
Dec 31, 2014 | 97 | 49 | 102.08% |
Dec 31, 2013 | 48 | 22 | 84.62% |
Dec 31, 2012 | 26 | 2 | 8.33% |
Dec 31, 2011 | 24 | -3 | -11.11% |
Dec 31, 2010 | 27 | 0 | - |
Dec 31, 2009 | 27 | -36 | -57.14% |
Dec 31, 2008 | 63 | -80 | -55.94% |
Dec 31, 2007 | 143 | 5 | 3.62% |
Dec 31, 2006 | 138 | 26 | 23.21% |
Dec 31, 2005 | 112 | 11 | 10.89% |
Dec 31, 2004 | 101 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Option Care Health | 8,058 |
QuidelOrtho | 7,000 |
HealthEquity | 3,208 |
Sotera Health Company | 3,000 |
Doximity | 977 |
agilon health | 747 |
Blueprint Medicines | 641 |
CRISPR Therapeutics AG | 458 |
ACAD News
- 10 days ago - Acadia Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024 - Business Wire
- 13 days ago - Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 18 days ago - Delaware District Court Rules in Favor of Acadia on Formulation Patent Construction (Markman) Claims Regarding NUPLAZID® (pimavanserin) - Business Wire
- 18 days ago - Delaware Federal District Court Rules in Favor of Acadia Pharmaceuticals in NUPLAZID® (pimavanserin) Patent Litigation - Business Wire
- 4 weeks ago - Acadia Pharmaceuticals Initiates Pivotal Phase 3 Study of Carbetocin (ACP-101) for the Treatment of Hyperphagia in Prader-Willi Syndrome - Business Wire
- 4 weeks ago - Acadia Pharmaceuticals Initiates Phase 2 Clinical Trial of ACP-204 for the Treatment of Alzheimer's Disease Psychosis - Business Wire
- 5 weeks ago - Acadia Pharmaceuticals Announces Change in Research and Development Leadership - Business Wire
- 2 months ago - Acadia Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operating Overview - Business Wire